These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7901030)

  • 1. Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-HT1A receptor agonist, buspirone, after prolonged chronic administration.
    Söderpalm B; Lundin B; Hjorth S
    Eur J Pharmacol; 1993 Aug; 239(1-3):69-73. PubMed ID: 7901030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
    Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.
    Ballarín M; Carceller A; Guitart X
    Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190.
    Routledge C; Gurling J; Ashworth-Preece MA; Dourish CT
    Eur J Pharmacol; 1995 Apr; 276(3):281-4. PubMed ID: 7601215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of apparent pA2 values for WAY 100635 at 5-HT1A receptors regulating 5-hydroxytryptamine release in anaesthetised rats.
    Assié MB; Koek W
    Eur J Pharmacol; 2000 Dec; 409(2):173-7. PubMed ID: 11104831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
    Schreiber R; De Vry J
    Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat.
    Assié MB; Lomenech H; Ravailhe V; Faucillon V; Newman-Tancredi A
    Br J Pharmacol; 2006 Sep; 149(2):170-8. PubMed ID: 16921393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
    Meller E; Goldstein M; Bohmaker K
    Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study.
    Routledge C; Gurling J; Wright IK; Dourish CT
    Eur J Pharmacol; 1993 Aug; 239(1-3):195-202. PubMed ID: 8223894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
    Protais P; Lesourd M; Comoy E
    Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex.
    Liu YP; Wilkinson LS; Robbins TW
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):175-85. PubMed ID: 14726995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone.
    Moser PC
    Psychopharmacology (Berl); 1989; 99(1):48-53. PubMed ID: 2528779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT-1A receptor responsiveness following subchronic administration of buspirone.
    Khan A; Haleem DJ
    Pak J Pharm Sci; 2006 Oct; 19(4):333-7. PubMed ID: 17105715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze test is abolished by previous administration of chlordiazepoxide or buspirone.
    Escarabajal MD; Torres C; Flaherty CF
    Life Sci; 2003 Jul; 73(8):1063-74. PubMed ID: 12818358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of serotonin depletion with anxiolytics and antidepressants on reticular-elicited hippocampal RSA.
    Zhu XO; McNaughton N
    Neuropharmacology; 1994 Dec; 33(12):1597-605. PubMed ID: 7760982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buspirone-induced changes in the serotonergic and non-serotonergic cells in the dorsal raphe nucleus of rats.
    Jahanshahi A; Lim LW; Steinbusch HW; Visser-Vandewalle V; Temel Y
    Neurosci Lett; 2010 Apr; 473(2):136-40. PubMed ID: 20178829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine.
    Hjorth S
    Eur J Pharmacol; 1996 May; 303(3):183-6. PubMed ID: 8813565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus.
    Matos FF; Korpinen C; Yocca FD
    Eur J Pharmacol; 1996 Dec; 317(1):49-54. PubMed ID: 8982718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-hippocampal buspirone in animal models of anxiety.
    Kostowski W; Płaźnik A; Stefański R
    Eur J Pharmacol; 1989 Sep; 168(3):393-6. PubMed ID: 2573536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin (5-HT) release in the dorsal raphé and ventral hippocampus: raphé control of somatodendritic and terminal 5-HT release.
    Matos FF; Urban C; Yocca FD
    J Neural Transm (Vienna); 1996; 103(1-2):173-90. PubMed ID: 9026372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.